NCT00018148View on ClinicalTrials.gov

Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

PHASE2CompletedINTERVENTIONAL
Enrollment

158

Participants

Timeline

Start Date

April 30, 1998

Primary Completion Date

December 31, 2002

Study Completion Date

January 31, 2003

Conditions
Smoking
Interventions
DRUG

nortriptyline

Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg

DRUG

transdermal nicotine

Transdermal nicotine 21 mg, titrated down plus placebo

Trial Locations (1)

80220

VA Eastern Colorado Health Care System, Denver, Denver

All Listed Sponsors
lead

US Department of Veterans Affairs

FED

NCT00018148 - Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation | Biotech Hunter | Biotech Hunter